Compare StocksMS vs WST

Morgan Stanley (MS) vs West Pharmaceutical Services, Inc. (WST): Which Is the Better Buy in 2026?

As of 2026-06-19, MS is undervalued at $223, with a DCF intrinsic value of $298 and a margin of safety of 25%. WST is overvalued at $328, with an intrinsic value of $184 and a margin of safety of -78%. Of the two, MS has the wider margin of safety.

MS
Morgan Stanley
$223.17
VS
WST
West Pharmaceutical Services, Inc.
$327.95

Rewards

MS
  • Gross margin of 87.4% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • Morgan Stanley scores 80/100 on the Economic Moat Score (Wide Moat), with revenue predictability as the strongest competitive dimension.
  • Each dollar of retained earnings has created $3.56 of earning power — management is an exceptional capital allocator.
WST
  • West Pharmaceutical Services, Inc. has maintained ROIC above 10% for 4 consecutive years, suggesting solid business economics.
  • Altman Z-Score of 13.89 indicates very low bankruptcy risk — the company is firmly in the safe zone.
  • Net debt/EBITDA of -0.2x means the company holds more cash than debt — a net cash position.

Risks

MS
  • Trailing P/E of 20.2x is 26% above the historical average of 16.1x — the stock trades at a premium to its own history.
  • PEG ratio of 2.66 indicates the stock is expensive relative to its expected growth — the market may be pricing in more growth than analysts project.
  • Altman Z-Score of 0.29 places the company in the distress zone — financial patterns resemble those of companies that experienced bankruptcy.
WST
  • FCF yield of 2.0% is below 3%, meaning the market is pricing in substantial future growth to justify the current price.
  • PEG ratio of 3.17 indicates the stock is expensive relative to its expected growth — the market may be pricing in more growth than analysts project.

Key Valuation Metrics

Learn more →
MS
WST
Valuation
N/A
Free Cash Flow
$468.90M
N/A
FCF Yield
2.02%
20.21
Trailing P/E
43.84
17.56
Forward P/E
34.32
Quality & Moat
3.38%
ROIC
16.67%
16.39%
ROE
19.13%
87.39%
Gross Margin
36.28%
2.66
PEG Ratio
3.17
Balance Sheet Safety
Net cash
Net Debt / Equity
Net cash
N/A
Interest Coverage
N/A
N/A
Net Debt / EBITDA
-0.23
1.81%
Dividend Yield
0.27%
MS: 6Ties: 1WST: 2
MSWST

Historical Fundamentals

Learn more →
MS

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

WST

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

$1 Retained Earnings Test

Learn more →
MS
$6.65
created per $1 retained over 3 years
Exceptional Value Creator
Σ Retained
$20.84B
Δ Market Cap
+$138.59B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
WST
$1.70
created per $1 retained over 3 years
Value Creator
Σ Retained
$1.40B
Δ Market Cap
+$2.38B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Discounted Cash Flow (DCF) Analysis

Learn more →
MS
25.0% Margin of Safety
Price is 25.0% below estimated fair value
Current Price: $223.17
Fair Value: $297.53
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued
WST
77.9% Overvalued
Price is 77.9% above estimated fair value
Current Price: $327.95
Fair Value: $184.37
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued

Reverse DCF — Market-Implied Growth

Learn more →
MS

Requires positive FCF to compute implied growth rate.

WST

What growth rate is the market pricing in at $328?

+19.2%
Market-Implied Owner Earnings Growth
Standard FCF implies +19.9%

The market implies +19.2% Owner Earnings growth, above historical trends.

Standard FCF implies a demanding +19.9%, reflecting heavy growth investment.

Economic Moat Score

Learn more →
MS
80/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None

Wide moat driven primarily by revenue predictability. Margin Stability is the area most vulnerable to competitive pressure.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
WST
68/100
Narrow Moat
70+ Wide · 40-69 Narrow · <40 None

Narrow moat with revenue predictability as the key competitive advantage. Improving margin stability would strengthen the moat.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.

Forensic Accounting

Learn more →
MS
-2.09
Possible Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
WST
-2.77
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Ownership Breakdown

Learn more →
MS
Insiders 24.3%Institutions 62.8%Retail & Other 12.9%
No. of Institutional Holders3,208
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
WST
Insiders 0.6%Institutions 104.0%
No. of Institutional Holders1,117
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

Insider Buying Activity

Learn more →
MS
0
Buys (3M)
1
Buys (12M)
Total value (12M): $5,630
PETERSON DOUGLAS L
Director
$5,630
@ $156.39 · 2025-10-17
Open market purchases · includes direct & indirect ownership · excludes option exercises
WST
0
Buys (3M)
0
Buys (12M)
No open market insider purchases found.
Open market purchases · includes direct & indirect ownership · excludes option exercises

Open market purchases · includes direct & indirect ownership · excludes option exercises.

Insider Selling Activity

Learn more →
MS
4
Sells (3M)
16
Sells (12M)
Total value (12M): $70.42M
GROSSMAN ERIC F
Officer
$2.12M
@ $190.75 · 2026-04-20
SIMKOWITZ DANIEL A
President
$2.78M
@ $189.24 · 2026-04-17
CRAWLEY MANDELL L.
Officer
$3.04M
@ $188.22 · 2026-04-16
SAPERSTEIN ANDREW MICHAEL
President
$9.74M
@ $188.59 · 2026-04-16
SIMKOWITZ DANIEL A
President
$6.02M
@ $182.61 · 2026-01-30
CRAWLEY MANDELL L.
Officer
$1.44M
@ $183.45 · 2026-01-20
YESHAYA SHARON
Chief Financial Officer
$2.94M
@ $185.77 · 2026-01-20
SMITH CHARLES AUBREY III
Officer
$1.55M
@ $182.08 · 2026-01-20
SAPERSTEIN ANDREW MICHAEL
President
$5.57M
@ $183.62 · 2026-01-20
GROSSMAN ERIC F
Officer
$3.97M
@ $184.00 · 2026-01-20
PIZZI MICHAEL A
Officer
$3.69M
@ $184.55 · 2026-01-20
PICK EDWARD N.
Chief Executive Officer
$16.43M
@ $164.34 · 2025-10-31
SMITH CHARLES AUBREY III
Officer
$2.81M
@ $140.30 · 2025-07-17
SIMKOWITZ DANIEL A
President
$4.09M
@ $141.13 · 2025-07-17
GROSSMAN ERIC F
Officer
$1.69M
@ $141.12 · 2025-07-17
PIZZI MICHAEL A
Officer
$2.53M
@ $140.62 · 2025-07-17
SIMKOWITZ DANIEL A
President
$3.70M
@ $127.37 · 2025-05-12
HERZ ROBERT H
Director
$95,459
@ $119.32 · 2025-05-02
SAPERSTEIN ANDREW MICHAEL
President
$4.80M
@ $120.00 · 2025-05-02
GROSSMAN ERIC F
Officer
$1.12M
@ $111.65 · 2025-04-15
CRAWLEY MANDELL L.
Officer
$1.15M
@ $138.06 · 2025-01-22
SAPERSTEIN ANDREW MICHAEL
President
$4.20M
@ $136.43 · 2025-01-21
SIMKOWITZ DANIEL A
President
$5.00M
@ $136.61 · 2025-01-21
AKRAM RAJA
Chief Financial Officer
$2.38M
@ $136.01 · 2025-01-21
GROSSMAN ERIC F
Officer
$1.78M
@ $136.20 · 2025-01-21
PIZZI MICHAEL A
Officer
$2.52M
@ $136.92 · 2025-01-21
CRAWLEY MANDELL L.
Officer
$368,375
@ $105.25 · 2024-07-26
AKRAM RAJA
Officer
$797,764
@ $106.37 · 2024-07-18
HERZ ROBERT H
Director
$106,621
@ $106.62 · 2024-07-17
SIMKOWITZ DANIEL A
President
$4.26M
@ $106.54 · 2024-07-17
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
WST
2
Sells (3M)
2
Sells (12M)
Total value (12M): $1.13M
FAVORITE ANNETTE F
Officer
$859,753
@ $305.20 · 2026-04-27
WINTERS CHAD
Officer
$269,399
@ $300.67 · 2026-04-27
WITHERSPOON CHARLES
Officer and Treasurer
$218,211
@ $310.40 · 2024-10-29
WITHERSPOON CHARLES
Officer and Treasurer
$308,700
@ $300.00 · 2024-08-19
GREEN ERIC MARK
Chief Executive Officer
$9.36M
@ $304.71 · 2024-08-06
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

🎭 Mr. Market's Mood

Learn more →
MS
FearGreed
😏Greed(70/100)

"Market is optimistic — be cautious and ensure you have a margin of safety"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
WST
FearGreed
😏Greed(64/100)

"Market is optimistic — be cautious and ensure you have a margin of safety"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

⚖️ Buffett Signal

Learn more →
MS
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Greed (70)
WST
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Greed (64)
View MS Full AnalysisView WST Full Analysis

Frequently Asked Questions: MS vs WST

Is Morgan Stanley or West Pharmaceutical Services, Inc. more undervalued in 2026?

Based on our discounted cash flow model, MS trades at a 25.0% margin of safety (intrinsic value $298 vs. price $223), compared to WST's -77.9% margin of safety (intrinsic $184 vs. $328).

Which stock has a wider economic moat, Morgan Stanley or West Pharmaceutical Services, Inc.?

MS scores 80/100 (Wide moat), while WST scores 68/100 (Narrow moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

Is Morgan Stanley in financial distress?

MS's Altman Z-Score of 0.3 places it in the Distress zone, signaling elevated bankruptcy risk. WST scores 13.9 (Safe zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

Which stock has higher return on invested capital, Morgan Stanley or West Pharmaceutical Services, Inc.?

WST earns 16.7% ROIC versus MS's 3.4%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

Which dividend is safer, Morgan Stanley's or West Pharmaceutical Services, Inc.'s?

WST's dividend earns a safety score of 94/100 (Very Safe), compared to MS's 79/100 (Safe). WST has raised its dividend for 3 consecutive years.